Impact of the modulator elexacaftor/tezacaftor/ivacaftor (ETI) on the complexity of prescriptions and the clinical stage of children and adolescents with cystic fibrosis. RSD [Internet]. 2026 Jan. 28 [cited 2026 Feb. 3];15(1):e7715150550. Available from: https://rsdjournal.org/rsd/article/view/50550